Navigation Links
Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
Date:12/9/2008

Findings confirm advantages of fixed-ratio drug delivery and lay the groundwork for Phase 2 trials already underway in first-line and first-relapse Acute Myeloid Leukemia (AML) settings

PRINCETON, N.J., Dec. 9 /PRNewswire/ -- Celator Pharmaceuticals today announced that a Phase 1 dose escalating study of CPX-351 (cytarabine:daunorubicin) Liposome Injection established the recommended dose for Phase 2 studies and confirmed preliminary observations of safety, enhanced pharmacokinetics and promising anti-tumor activity in patients with advanced leukemia. A final analysis of the Phase 1 data (abstract #2984) and supportive findings from a pre-clinical pharmacodynamic model (abstract #942) were presented at the 50th American Society of Hematology (ASH) Annual Meeting in San Francisco.

"In the Phase 1 trial, CPX-351 had a tolerability profile that appears better than conventional cytarabine/daunorubicin treatment and produced impressive anti-leukemic responses, including complete remissions (CRs) at and below the maximum tolerated dose, in relapsed and refractory patients," said Eric J. Feldman, MD, of the Weill Medical College of Cornell University and New York-Presbyterian Hospital, the principal investigator in the study. "These encouraging results suggest that CPX-351 may offer advantages to conventional administration of these commonly used drugs. We are excited to participate in the two Phase 2 studies."

In the study, complete remissions were observed in 11 of 47 patients, including 10 patients (9 CRs and 1 CRp - complete remission without full platelet recovery) of 44 with AML and 1 patient of 3 with acute lymphocytic leukemia (ALL) following treatment with CPX-351. Of the 10 AML CRs, 7 occurred at the two highest dose levels, although complete remissions were achieved at dose levels as little as one third of the maximum tolerated dose (MTD). Of note, 7 CRs were achieved in 22 patient
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals
2. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
3. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
4. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
5. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
6. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
7. Memory Pharmaceuticals Receives NASDAQ Decisions
8. MAP Pharmaceuticals to Present at the 2008 RBC Capital Markets Healthcare Conference
9. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
10. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
11. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 A new ... a 63% increase in disability associated with speech problems ... a more than 15% increase in disability associated with ... intervention for rising numbers of children who are experiencing ... (ASHA). , On a broader level, the ...
(Date:8/21/2014)... is to focus on her body in terms of ... her as a complete human being with thoughts and ... in the media, how does it affect individual romantic ... Quarterly , a SAGE journal, finds that more objectification ... incidents of sexual pressure and coercion., Researchers Laura R. ...
(Date:8/21/2014)... FRANCISCO Aug. 21, 2014 Researchers in the ... congenital cataracts can quickly and accurately diagnose a number ... a study published online today in ... Ophthalmology. Using a single test, doctors were able ... on their mutations reducing the time and money spent ...
(Date:8/21/2014)... 2014 Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) ... suffer uncontrollable internal bleeding and other serious injuries continue ... According to court documents, a wrongful death lawsuit was ... District of New York by the family of a ... that was allegedly caused by Xarelto. Among other thing, ...
(Date:8/21/2014)... 21, 2014 The report "Industrial ... Pollutant Control System (FGD, DeNOx, Particulate Control, Mercury ... Steel, Chemical & Others) - Global Trends & ... industrial flue gas treatment systems & services market ... size in terms of value. The industrial flue ...
Breaking Medicine News(10 mins):Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 3Health News:Objectification in romantic relationships related to sexual pressure and coercion 2Health News:New DNA test for diagnosing diseases linked to childhood blindness 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 3Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 4Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4
... WASHINGTON, July 22 The role of personal responsibility in ... Rethinking Responsibility: Reflections on Sex and Accountability. Released ... nonprofit, nonpartisan organization, the volume includes 29 essays written by leaders ... , Leading media voices, ...
... July 22 To help employers face the challenges of ... difficult economy, Sodexo, Inc., now offers a Quality of Life ... today the launch of the program designed to ... , , Sodexo, a ...
... , DALLAS, July 22 Texas ... Heart Association for providing quality, evidence-based care for coronary artery ... "This is another example of the dedication and commitment ... Dallas community by physicians, nursing, allied health professionals and administration," ...
... , WALNUT CREEK, Calif., July 22 ... cure with the recent approval by The National Institutes of Health ... scientists, parents and advocates. , , ... to highlight the work of the NIH,s Research Plan on Fragile ...
... demands of surgical careers, most surgeons would still choose their ... postpone having children or to not have children at all ... national survey conducted by UC Davis researchers has found. The ... Surgery , one of the JAMA/Archives journals. "Surgery is ...
... associated with varied, disproportionate, asymmetric overgrowth of many ... seen in Proteus syndrome is progressive and difficult ... treatment for the progressive overgrowth of tissue over ... functional and cosmetic consequences, so surgical intervention is ...
Cached Medicine News:Health News:National Leaders Examine Sex and Responsibility in New Book 2Health News:National Leaders Examine Sex and Responsibility in New Book 3Health News:Sodexo Offers Landmark Program to Promote Employee Health and Worklife Balance 2Health News:Texas Health Dallas Receives Double Honor From American Heart Association 2Health News:NIH Plan Charts Course to Better Treatments and Cure for Most Common Known Genetic Cause of Autism: Fragile X 2Health News:UC Davis study highlights work-life issues of female surgeons 2
(Date:8/21/2014)... 21, 2014   Memorial Hermann Health System and ... today announced a new partnership to provide a new level ... care centers in the greater Houston ... become the exclusive provider of professional breast radiology services for ... Memorial City, The Woodlands , Northeast, Southwest ...
(Date:8/21/2014)... Aug. 21, 2014  Publicis Groupe customer engagement ... Managing Partner and Healthcare Industry Group Leader, has been ... recognizes the most inspiring people in the life-sciences industry. ... research and development, marketing, technology, creativity, strategy and medicine. ... as a partner in its leading Rosetta Consulting practice. ...
(Date:8/21/2014)... HAMBURG, Germany , Aug. 21, 2014  IBM (NYSE: ... Deutsches Elektronen-Synchrotron ( DESY ), a leading national research ... up management and storage of massive volumes of x-ray ... architecture based on IBM software defined technology can handle ... peak performance and help scientists worldwide gain faster insights ...
Breaking Medicine Technology:Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Shannon Hartley Shines in PharmaVOICE 100 2DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3
... Propel Cannulated Interference Screw ... unbiased, symmetrical starts, while limiting ... distal end reduces abrasion where ... unequalled protection. Aggressive-pitch thread enables ...
... Interference Screws. Optimal screw ... graft selection options. Robust ... deformation, and chamfered screw ... atraumatic tissue fixation. Features ...
Cannulated Interference Screws...
Stryker Endoscopy offers a wide variety of small-joint arthroscopes that produce a brilliant high-resolution image without sacrificing Stryker's ultra-high tip durability....
Medicine Products: